ProCE Banner Activity

KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

Slideset Download
Conference Coverage
ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology